Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Märsch

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Combinatorial Chemistry & High Throughput Screening|March 14, 2008
Artificial evolution with adeno-associated viral librariesLuca Perabo, Anke Huber, Stephan Märsch, et al.
Expert Opinion on Drug Discovery|June 23, 2025
The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?Omar Abdelmotaleb, Anneliese Schneider, Christian Gassner, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Mabs|November 6, 2025
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Anneliese Schneider, Inja Waldhauer, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Combinatorial Chemistry & High Throughput Screening|March 14, 2008
Artificial evolution with adeno-associated viral librariesLuca Perabo, Anke Huber, Stephan Märsch, et al.
Expert Opinion on Drug Discovery|June 23, 2025
The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?Omar Abdelmotaleb, Anneliese Schneider, Christian Gassner, et al.
Cancers|November 25, 2020
IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic MalignanciesDennis Kirchhoff, Beatrix Stelte-Ludwig, Hans-Georg Lerchen, et al.
Mabs|November 6, 2025
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBsOmar Abdelmotaleb, Anneliese Schneider, Inja Waldhauer, et al.
Pageof 1